迪哲医药(688192) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥134,900,880, representing a 236.39% increase compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥213,709,642.17, with a year-to-date net profit of -¥558,460,529.94[2]. - The weighted average return on equity for Q3 2024 was -41.20%, down from -85.92% year-to-date[3]. - The company reported a net cash flow from operating activities of -¥162,361,573.91 for Q3 2024, with a year-to-date figure of -¥463,308,340.42[2]. - The net profit for Q3 2024 was -649,647,448.06 RMB, an improvement from -828,949,591.21 RMB in Q3 2023, indicating a reduction in losses by approximately 21.6%[20]. - The total operating profit for Q3 2024 was -651,046,906.08 RMB, compared to -828,916,026.19 RMB in the same period last year, reflecting a year-over-year improvement of about 21.4%[20]. - The company reported a total comprehensive income of -649,647,448.06 RMB for Q3 2024, compared to -828,949,591.21 RMB in Q3 2023, showing a year-over-year improvement[21]. Research and Development - Research and development expenses totaled ¥184,958,456.88 in Q3 2024, accounting for 137.11% of revenue, a decrease of 450.2 percentage points year-on-year[3]. - Research and development expenses for the first three quarters of 2024 were CNY 567,728,545.76, slightly lower than CNY 578,964,914.76 in the previous year[19]. - The company accelerated its product development investments, leading to significant losses but also increased sales from newly approved innovative drugs[6]. - The company’s new drug, Goliqizhen (generic name: Goliqizhen Capsules), received approval from NMPA for treating r/r PTCL, showing an objective response rate (ORR) of 44.3%[12]. - The company’s new lung cancer drug, Shuwozhe (generic name: Shuwotini Tablets), received Breakthrough Therapy Designation for treating EGFR Exon20ins NSCLC[13]. - The median overall survival (OS) for patients treated with Goliqizhen reached 24.3 months[13]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,642,509,057.58, an increase of 9.77% from the end of the previous year[3]. - The company's total assets increased to CNY 1,642,509,057.58 in Q3 2024, up from CNY 1,496,378,567.44 in Q3 2023[18]. - The total liabilities of the company reached CNY 1,205,262,190.98 in Q3 2024, compared to CNY 647,751,151.64 in the same quarter of 2023[17]. - The company's equity attributable to shareholders decreased by 49.51% year-on-year, primarily due to ongoing losses[8]. - The company's equity attributable to shareholders decreased to CNY 428,433,784.72 in Q3 2024 from CNY 848,627,415.80 in Q3 2023[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,642[9]. - The largest shareholder, Advanced Manufacturing Industry Investment Fund, holds 108,923,023 shares, representing 26.21% of total shares[9]. - The company has a total of 57,451,788 shares held by Jiangsu Wuxi Dizhe Enterprise Management Partnership, accounting for 13.82% of total shares[9]. - The company has not reported any changes in the lending of shares for margin trading among the top shareholders[11]. Cash Flow and Financing - The company reported cash and cash equivalents of RMB 130,831,963.06, an increase from RMB 74,201,573.96 in the previous period[15]. - Cash flow from operating activities for the first three quarters of 2024 was -463,308,340.42 RMB, an improvement from -669,132,575.97 RMB in the same period of 2023[23]. - The company reported cash inflow from operating activities totaling 387,967,942.27 RMB in Q3 2024, significantly higher than 26,305,772.19 RMB in Q3 2023[23]. - The net cash flow from financing activities for Q3 2024 was 606,803,240.41 RMB, compared to 175,902,153.78 RMB in Q3 2023, indicating a significant increase in financing[24]. - The company recorded investment cash inflow of 2,709,870,267.04 RMB in the first three quarters of 2024, compared to 3,468,191,094.88 RMB in the same period of 2023[23]. Operating Costs - Total operating revenue for the first three quarters of 2024 reached CNY 338,451,000, a significant increase from CNY 40,102,400 in the same period of 2023[19]. - Total operating costs for the first three quarters of 2024 amounted to CNY 1,031,763,876.35, compared to CNY 896,482,852.81 in 2023, indicating a rise in costs[19]. - Short-term borrowings increased to CNY 235,184,441.10 in Q3 2024, up from CNY 200,114,966.97 in the previous year[17]. - The company’s long-term borrowings surged to CNY 584,395,297.38 in Q3 2024, compared to CNY 138,313,291.49 in Q3 2023, indicating a significant increase in leverage[17].